Making phase I drug development
simple, reliable and predictable through forensic analysis of pharmacokinetic data
John A Roush, PhD
Owner, Vista Biopharmaceutics
John Roush has 20 years experience in supporting drug product development, through modeling, simulations and forensic analysis of pharmacokinetic data. John pioneered the method called ARA Biopharmaceutics review, which extracts the important details of oral drug absorption from pharmacokinetic data. This method gives investigators a second sight, allowing them to accurately visualize how a drug product and the body interact, as it passes through the gastrointestinal tract. John has used this method to make high value contributions to more than 100 drug development projects, since the method was first published in 2011.
John has contributed to the development of 14 currently approved medicines and is a co-inventor of Augmentin XR, which is the first sustained release oral antibiotic approved in the US and Europe.